What's Going On With Windtree Therapeutics Stock Wednesday?
What's Going On With Windtree Therapeutics Stock Wednesday?
One key difference between this study and the SEISMiC Phase 2 clinical study is that the company is using a longer dosing duration and tapering the dosage to analyze potential benefits. Specifically, the study will extend the dosing duration from 24 hours to 60 hours. Additionally, one group of participants in the study will receive a constant dose of istaroxime, while another group will receive a decreasing dosage.Windtree Therapeutics, Inc. (NASDAQ:WINT) shares are trading higher Wednesday after the company completed enrollment of its SEISMiC Extension Phase 2b study of istaroxime in early cardiogenic shock caused by heart failure.
Windtree Therapeutics, Inc. (納斯達克:WINT)股價週三上漲，公司完成了其SEISMiC Extension Phase 20億的伊斯他諾辛在早期心源性休克（由心力衰竭引起）的研究招募。
The Details: The company is hoping to build on the positive results from a previous study, the SEISMiC Phase 2 clinical study, regarding the ability of istaroxime to improve heart function and low blood pressure in the context of early cardiogenic shock due to heart failure.
公司希望在之前的研究SEISMiC Phase 2臨床研究的積極結果基礎上繼續發展，該研究與伊斯他諾辛改善心臟功能和低血壓在早期心源性休克的情況下有關。
Also, Windtree Therapeutics hopes that the study confirms its observations from the prior study that the drug has a favorable renal profile and does not increase cardiac arrhythmias.
此外，Windtree Therapeutics希望該研究能夠證實其先前觀察到的有利腎臟特性，且不會增加心臟心律失常的觀察結果。
One key difference between this study and the SEISMiC Phase 2 clinical study is that the company is using a longer dosing duration and tapering the dosage to analyze potential benefits. Specifically, the study will extend the dosing duration from 24 hours to 60 hours. Additionally, one group of participants in the study will receive a constant dose of istaroxime, while another group will receive a decreasing dosage.
該研究與SEISMiC Phase 2臨床研究的一個關鍵區別在於公司採用了更長的給藥持續時間，並遞減劑量以分析潛在好處。具體來說，該研究將把給藥持續時間從24小時延長到60小時。此外，研究中的一組參與者將接受伊斯他諾辛的恒定劑量，而另一組將接受遞減劑量。
"We look forward to announcing topline results from the SEISMiC Extension Study by the end of the month and plan to present this data at a major medical meeting in the very near future," said Steve Simonson, chief medical officer and senior vice president of Windtree.
"我們期待在本月底宣佈SEISMiC Extension Study的最終結果，並計劃在不久的將來在一次重要醫學會議上展示這些數據，"迎風集團首席醫療官、高級副總裁史蒂夫·西蒙森說。
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
儘管進行了醫療保險談判，美國人可能仍需支付更多的處方藥費
WINT Price Action: At the time of writing, Windtree stock is moving 18.6% higher at $3.78, according to data from Benzinga Pro.
WINT股價表現：截至目前，Windtree股票的股價上漲18.6%，報3.78美元，數據來自Benzinga Pro。
Image: Emilian Danaila from Pixabay
圖片：來自Pixabay的Emilian Danaila
譯文內容由第三人軟體翻譯。
